RT @ATRIUMRx: ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their r…
ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their recommendations for SGLT-2 inhibitors and GLP-1RAs for this patient population #cardioed #foamed https://t.co/i6sjrANy4y https://t.c
RT @acorderofort: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @Cardio_delaGuia: Consenso #ACC sobre nuevos fármacos #diabetes y efectos CV. Analizan 2 inhibidores SGLT2 (empa y canagliflozina) y 4 G…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @Cardio_delaGuia: Consenso #ACC sobre nuevos fármacos #diabetes y efectos CV. Analizan 2 inhibidores SGLT2 (empa y canagliflozina) y 4 G…
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
RT @doctorheart00: A estudiar el consenso 2018 en el manejo de la Diabetes tipo II y enfermedad Arterioesclerosa. https://t.co/s8qh01xa0i…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @Cardio_delaGuia: Consenso #ACC sobre nuevos fármacos #diabetes y efectos CV. Analizan 2 inhibidores SGLT2 (empa y canagliflozina) y 4 G…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With #T2D and Atherosclerotic Cardiovascular Disease https://t.co/QxEeTZS8v8 @ACCinTouch https://t.co/zFDFjICZx3
RT @IlindelatorreMD: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con di…
RT @acorderofort: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @Inma16: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabete…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/N6K59p8hLc
RT @FarmaMadridAP: (JACC) Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes c…
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
A must read paper 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/EmOyX2JWA7
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @IlindelatorreMD: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con di…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
I spent yesterday after clinic learning more about SGLT2-inhibitors. We can’t avoid it anymore 😬 prescribe > defer/refer? 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients w/DM2 and Atherosclerotic CVD https
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @IlindelatorreMD: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con di…
RT @IlindelatorreMD: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con di…
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @IlindelatorreMD: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con di…
RT @acorderofort: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con diabetes tipo 2 y enfermedad cardiovascular aterosclerótica | Journal of the American College of Cardiology. https://t.co/GvUjAf7cnl
Consenso #ACC sobre nuevos fármacos #diabetes y efectos CV. Analizan 2 inhibidores SGLT2 (empa y canagliflozina) y 4 GLP-1RAs (liraglutida, semaglutida, exenatida y lixisenatida). Los cardiólogos debemos empezar a involucrarnos activamente @JACCJournals ht
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @SJGreene_md: A really great resource that will hopefully improve cardiologist comfort with discussing these therapies with patients and…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. https://t.co/uArK0sSdeg https://t.co/ToTgv16QVq
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @ShusShoes: @CPMCCardioFITs @jonmwong8 Hopefully we can get our faculty on board with this https://t.co/HIRdvBx4a7
@CPMCCardioFITs @jonmwong8 Hopefully we can get our faculty on board with this
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/S8h2Vw0x7P
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for #cardiovascular Risk Reduction in Patients With Type 2 #diabetes and Atherosclerotic cardiovascular #diseases https://t.co/Au7UjujUzr https://t.co/KwjUpkEobw
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @NadaHassib1: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
Solo el 13% de paciente atendidos ambulatoriamente por patología coronaria en EEUU son diagnosticados de DM 2. Según datos de programa PINNACLE 😐. Esperemos que con los actuales datos más pacientes sean diagnosticados y se beneficien. 😉 https://t.co/kKehBr
RT @NadaHassib1: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @IAmDrIbrahim: These are our therapies! This is great. We have to get comfortable prescribing https://t.co/YqdFeUAipA
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @yaleHFdoc: Congrats to @JJheart_doc and the @JACCJournals team for this extremely important document! This will help us do so much bett…
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
We endorse @ACCinTouch's new 2018 Expert Consensus Decision Pathway, which addresses the changing paradigm in how cardiovascular specialists should approach care of patients w/ #T2D. Full report: https://t.co/HGLbdw8f7c
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/vJMo8P8HuI
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…